Maysa Abu Khalaf, MD

Maysa Abu Khalaf, MD

Contact Dr. Abu Khalaf

1025 Walnut Street
Suite 700
Philadelphia, PA 19107

(215) 503-5088
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
  2. A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia
  3. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
  4. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer
  5. Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications
  6. Impacts of early guideline-directed 21-gene recurrence score testing on adjuvant therapy decision making
  7. Racial and ethnic disparities in oncotype DX test receipt in a statewide population-based study
  8. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
  9. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition
  10. Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer
  11. Patient preferences regarding incidental genomic findings discovered during tumor profiling
  12. New strategies in breast cancer: Immunotherapy
  13. Mutation based treatment recommendations from next generation sequencing data: A comparison of web tools
  14. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer
  15. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008–2011
  16. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer
  17. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma
  18. Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers
  19. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
  20. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy